AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
171.68
+0.74 (+0.43%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close170.94
Open172.43
Bid0.00 x 0
Ask0.00 x 0
Day's Range170.60 - 174.59
52 Week Range160.07 - 256.80
Volume4,207,156
Avg. Volume3,897,495
Market Cap57.098B
Beta1.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.80 (1.65%)
Ex-Dividend Date2017-11-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer Remix: Yes, Allergan is the anti-bitcoin
    CNBC Videos9 days ago

    Cramer Remix: Yes, Allergan is the anti-bitcoin

    Jim Cramer pointed to the drug player for its lack of volatility, and said none of its redeeming qualities really matter to investors anymore.

  • Cramer's lightning round: Energy Transfer Partners is wor...
    CNBC Videos9 days ago

    Cramer's lightning round: Energy Transfer Partners is wor...

    Jim Cramer zoomed through his take on callers' favorite stocks, including a bedraggled energy stock.

  • John Griffin: A Former Tiger Cub"s Wavering Fortunes
    GuruFocus.comyesterday

    John Griffin: A Former Tiger Cub"s Wavering Fortunes

    The founder of Blue Ridge Capital tries to keep up with former glories

  • A ‘Better Botox’ May Target Millennials, Men and Hesitant Women
    Bloomberg2 days ago

    A ‘Better Botox’ May Target Millennials, Men and Hesitant Women

    Revance Therapeutics Inc’s lead asset is a new form of botulinum toxin, akin to the best-selling wrinkle eraser, Botox, but with a key difference, durability, according to Chief Executive Officer Daniel ...

  • Barrons.com2 days ago

    Valeant: Down It Goes!

    Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkey3 days ago

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Reuters3 days ago

    U.S. appeals court vacates conviction of drug distributor over Botox

    A U.S. appeals court on Wednesday vacated the conviction of the owner of a wholesale drug distributor accused of selling authentic Botox and other drugs with foreign labels, dealing another setback to the government, which has struggled at times to successfully prosecute similar such cases. A three-judge panel on the U.S. Court of Appeals for the Second Circuit found that a lower court erred when it declined to allow William "Liam" Scully to introduce evidence at his 2015 trial showing he sought legal advice about importing drugs with foreign labels from one of his lawyers. "I'm so happy with the court's decision to grant Liam a new trial and I look forward to him coming home," his wife, Suzanne Scully, told Reuters.

  • Allergan Inks Deal to Buy Texas-Based Repros Therapeutics
    Zacks3 days ago

    Allergan Inks Deal to Buy Texas-Based Repros Therapeutics

    Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.

  • Forbes3 days ago

    Woman-Led 'Drybar For Botox' Chain Alchemy 43 Grows -- With Drybar Founders' Backing

    Founder Nicci Levy recently closed a $3.2 million seed round for Alchemy 43, with backers including Kirsten Green's venture capital firm Forerunner Ventures and -- perhaps appropriately -- Drybar's Alli Webb and her brother and cofounder Michael Landau.

  • 10 More Losers That Will Be Stocks to Buy in 2018
    InvestorPlace3 days ago

    10 More Losers That Will Be Stocks to Buy in 2018

    Many healthcare stocks have been weak, with notable declines for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Celgene Corporation (NASDAQ:CELG), among others. All told, even though market headlines have screamed good news, a lot of stocks have been left out in the cold. A 10% drop in Kraft Heinz Co (NASDAQ:KHC) doesn’t sound like all that much, but in the context of a roaring broad market and what should be a stable trading pattern, it is.

  • 3 Drug/Biotech Stocks Up More Than 10% This Week
    Zacks4 days ago

    3 Drug/Biotech Stocks Up More Than 10% This Week

    The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

  • American City Business Journals5 days ago

    Allergan to buy Woodlands-based drug company

    Pharmaceutical giant Allergan PLC (AGN) will acquire The Woodlands-based Repros Therapeutics Inc. (RPRX), a company that develops drugs to treat male and female reproductive disorders, according to a Dec. 12 press release. A subsidiary of Ireland-based Allergan will purchase all of the outstanding shares of Repros common stock through a cash tender offer for 67 cents per share. Allergan — formerly Actavis PLC — reported net revenue of $14.57 billion in 2016, according to its annual report.

  • GuruFocus.com6 days ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: American Assets Trust, Aptiv PLC, TiVo, Allergan PLC and CenturyLink

  • Market Realist6 days ago

    Allergan on the Street: Analyst Recommendations This December

    As of December 6, 2017, of the 24 analysts tracking Allergan stock, 17 recommend a “buy,” while seven recommend a “hold.” None recommends a “sell."

  • Market Realist6 days ago

    What Are Analysts Estimating for Allergan Today?

    AGN's analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).

  • Market Realist6 days ago

    Inside Allergan’s International Segment in 3Q17

    The International segment reported revenues of $808 million in 3Q17, which was 15.8% higher than its revenues of $698 million in 3Q16.

  • GuruFocus.com7 days ago

    Weekly Top Insider Buys Highlight for the Week of Dec. 8

    The largest Insider Buys this week were for Allergan PLC (AGN), Kinder Morgan Inc. (KMI), Annaly Capital Management Inc. (NLY), and Andeavor Logistics LP (ANDX).

  • Bill Ackman Likely to Face Trial on Allergan Insider-Trading Claims
    Bloomberg8 days ago

    Bill Ackman Likely to Face Trial on Allergan Insider-Trading Claims

    Activist investor Bill Ackman and his estranged former collaborator in a 2014 hostile takeover bid for Botox-maker Allergan Inc. will likely face a jury trial next month over claims they engaged in insider ...

  • 3 Drug/Biotech Stocks Up More Than 10% This Week
    Zacks8 days ago

    3 Drug/Biotech Stocks Up More Than 10% This Week

    The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

  • Capital Cube8 days ago

    ETFs with exposure to Allergan Plc : December 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Allergan Plc Here are 5 ETFs with the largest exposure to AGN-US. Comparing the performance and risk of Allergan Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Market Realist9 days ago

    Inside Allergan’s US General Medicines in 3Q17

    The US General Medicines segment reported revenues of $1.497 billion in 3Q17, which was 0.6% higher than its $1.488 billion in 3Q16.

  • Market Realist9 days ago

    Inside Allergan’s US Specialized Therapeutics in 3Q17

    For 3Q17, this segment reported an 18.7% YoY (year-over-year) growth in revenues to $1.72 billion, compared with its revenues of $1.45 billion in 3Q16.

  • Market Realist9 days ago

    Breaking down Allergan’s Business Segments in 3Q17

    This segment's revenues rose 18.7% YoY (year-over-year) to $1.72 billion in 3Q17, compared with $1.45 billion in 3Q16.

  • Cramer Remix: Yes, Allergan is the anti-bitcoin
    CNBC9 days ago

    Cramer Remix: Yes, Allergan is the anti-bitcoin

    Jim Cramer pointed to the drug player for its lack of volatility, and said none of its redeeming qualities really matter to investors anymore.